"Arabinonucleosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nucleosides containing arabinose as their sugar moiety.
| Descriptor ID |
D001087
|
| MeSH Number(s) |
D13.570.065
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Arabinonucleosides".
Below are MeSH descriptors whose meaning is more specific than "Arabinonucleosides".
This graph shows the total number of publications written about "Arabinonucleosides" by people in this website by year, and whether "Arabinonucleosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 7 | 1 | 8 |
| 2004 | 3 | 1 | 4 |
| 2005 | 5 | 0 | 5 |
| 2006 | 6 | 1 | 7 |
| 2007 | 3 | 1 | 4 |
| 2008 | 3 | 2 | 5 |
| 2009 | 5 | 0 | 5 |
| 2010 | 5 | 3 | 8 |
| 2011 | 2 | 1 | 3 |
| 2012 | 8 | 3 | 11 |
| 2013 | 3 | 2 | 5 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 5 | 6 |
| 2016 | 4 | 1 | 5 |
| 2017 | 2 | 1 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Arabinonucleosides" by people in Profiles.
-
Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):783-788.
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
-
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589.
-
Imaging Findings in Children Presenting with CNS Nelarabine Toxicity. AJNR Am J Neuroradiol. 2022 12; 43(12):1802-1809.
-
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 12 01; 127(23):4421-4431.
-
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598.
-
Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial? J Clin Oncol. 2021 02 20; 39(6):694.
-
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 10 01; 38(28):3282-3293.
-
Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2020 11; 61(11):2775-2777.
-
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. J Clin Oncol. 2020 09 10; 38(26):3062-3070.